首页> 美国卫生研究院文献>Postgraduate Medical Journal >Shrinkage of thyrotrophin secreting pituitary adenoma treated with octreotide.
【2h】

Shrinkage of thyrotrophin secreting pituitary adenoma treated with octreotide.

机译:奥曲肽治疗促甲状腺素分泌垂体腺瘤的收缩。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Thyrotrophin secreting pituitary adenomas are a rare cause of recurrent thyrotoxicosis. We report on a 47 year old woman with an 8-year history of this condition. In this case the somatostatin analogue, octreotide, normalized thyroid hormone levels. It was associated with marked tumour shrinkage, with striking reduction of the suprasellar extension and improved appearances in the region of the left cavernous sinus shown by high resolution computerized tomography. Following surgery she developed a biochemical relapse which responded to the reinstitution of octreotide. On long term treatment she developed stomach cramps and gallstones. Octreotide was discontinued. We review previous reports of this condition and discuss the role of octreotide in its management.
机译:促甲状腺素分泌垂体腺瘤是复发性甲状腺毒症的罕见原因。我们报告了一位47岁的女性,有8年的这种病史。在这种情况下,生长抑素类似物奥曲肽使甲状腺激素水平正常化。它与显着的肿瘤缩小,上鞍延伸明显减少以及高分辨率海绵体层摄影术显示的左海绵窦区域的外观改善有关。手术后,她发生了生化复发,对奥曲肽的恢复有反应。经过长期治疗,她出现了胃痉挛和胆结石。奥曲肽停产。我们回顾了这种情况的先前报告,并讨论了奥曲肽在其管理中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号